123654-27-3

Basic information

• Product Name: (-)-(R)-2-aminomethylpyrrolidine
• CAS NO: 123654-27-3
• Molecular Weight: 100.164
• Mol File: 123654-27-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (-)-(R)-2-aminomethylpyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (-)-(R)-2-aminomethylpyrrolidine(123654-27-3)
• EPA Substance Registry System: (-)-(R)-2-aminomethylpyrrolidine(123654-27-3)

Safety Data

• Hazardous Substances Data: 123654-27-3(Hazardous Substances Data)

Upstream product

• 62937-45-5 (R)-prolinamide 
• 344-25-2 D-Prolin 
• 62937-47-7 (2R)-2-carbamoyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 259537-92-3 tert-butyl (2R)-2-(aminomethyl)pyrrolidine-1-carboxylate 
• 6404-31-5 Z-D-proline 

Downstream Products

• 956468-16-9 N-[((2R)-1-{[3,4-bis(methyloxy)phenyl]sulfonyl}-2-pyrrolidinyl)methyl]-3,4-bis(methyloxy)benzenesulfonamide 
• 1206103-64-1 (4aS,13aR)-8-bromo-10-[(phenylmethyl)oxy]-2,3,4a,5,13,13a-hexahydro-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-9,11-dione 
• 956467-82-6 N-[((2R)-1-{[3,4-bis(methyloxy)phenyl]sulfonyl}-2-pyrrolidinyl)methyl]-3,4-bis(methyloxy)benzenesulfonamide 

Relevant articles and documents

Enantioselective Synthesis of 2-Aminomethyl and 3-Amino Pyrrolidines and Piperidines through 1,2-Diamination of Aldehydes

An efficient method for the synthesis of 1,2-diamines from aldehydes through proline-catalyzed asymmetric α-amination followed by reductive amination is reported. The products resemble those obtained through direct asymmetric diamination of terminal alkenes. The methodology is used to synthesize 2-aminomethyl and 3-amino pyrrolidines and piperidines in high yields and with a good enantioselectivity. The usefulness of the method is demonstrated through the synthesis of a 2-aminomethyl iminocyclitol.

Biomimetic asymmetric aldol reactions catalyzed by proline derivatives attached to β-cyclodextrin in water

Two proline derivatives, (S)-2-aminomethylpyrrolidine and (R)-2-aminomethylpyrrolidine modified β-CD (CD-1, CD-2) were synthesized in the yields of 31% and 14%. Their self-inclusion conformations were characterized by 1H ROESY NMR studies and q

CHEMICAL COMPOUNDS

The present invention relates generally to novel therapeutic compounds and AXOR 109 agonists, and processes for the manufacture and use of the same.